# Spruce Biosciences, Inc. (SPRB)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001683553 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001683553))
- Full page: https://inspectstocks.com/stocks/sprb
- Data as of: price 2026-09-28; newest filing used 2026-08-12; latest fiscal period ended 2026-06-30

## Grade

**F** on the growth-and-cash rubric, 0 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | failed | $0.00 | $0.00 |
| Revenue growing recently | failed | $0.00 | $4.9M |
| Free cash flow positive | failed | -$56M |  |
| Free cash flow growing overall | failed | -$56M | -$36M |
| Free cash flow growing recently | failed | -$56M | -$33.3M |

Business quality (the + / − mark): 1 of 2 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Good return on equity | failed | -120.8% |  |
| Debt under control | passed | 0.02 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $0.00 |
| Net income, trailing twelve months | -$51.4M |
| Free cash flow, trailing twelve months | -$56M |
| Return on equity | -120.8% |
| Debt to equity | 0.02 |
| Share price | $47.73 |
| Market value | $137.2M |

## More on this company

- [Overview](https://inspectstocks.com/stocks/sprb)
- [Financial statements](https://inspectstocks.com/stocks/sprb/financials)
- [Competitors](https://inspectstocks.com/stocks/sprb/peers)
- [Earnings](https://inspectstocks.com/stocks/sprb/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.